Using the APP<sup>NL-F</sup>/MAPT double knock-in mouse model (dKI) and AD patient-derived brain organoids, we found that abemaciclib robustly ameliorates cognitive deficits and reduces neurodegeneration without altering amyloid burden or glial activation. This evidence concerns the gene APP and Alzheimer disease.